尽管肝病治疗的 III 期试验取得了进展，但 Galmed Pharmaceuticals 认为空头股数有所增加。 Galmed Pharmaceuticals sees rise in short interest despite Phase III trials progress for liver disease treatment.

Galmed制药公司是一家发展肝病治疗的生物制药公司,11月短期利息上升了31%,售价为22 800股。 Galmed Pharmaceuticals, a biopharmaceutical company developing treatments for liver diseases, saw a 31% rise in short interest in November, with 22,800 shares sold short. 该公司的股票价格在11月30日升至2.97美元,但跌至低于200天移动平均数。 The company's stock price rose to $2.97 on November 30th, though it has fallen below its 200-day moving average. StockNews.com以“销售”评级开始报导。 StockNews.com initiated coverage with a "sell" rating. Galmed目前正在第三阶段对Aramchol进行试验,Aramchol是非酒精类肝炎(NASH)的口服疗法。 Galmed is currently in Phase III trials for Aramchol, an oral therapy for non-alcoholic steato-hepatitis (NASH).